Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q16873

UPID:
LTC4S_HUMAN

ALTERNATIVE NAMES:
Glutathione S-transferase LTC4; Leukotriene-C(4) synthase; Leukotriene-C4 synthase

ALTERNATIVE UPACC:
Q16873; Q8N6P0; Q9UC73; Q9UD18

BACKGROUND:
Leukotriene-C4 synthase, with alternative names such as Glutathione S-transferase LTC4, is crucial for the conjugation of leukotriene A4 with glutathione, leading to the formation of leukotriene C4. This enzyme's specificity extends to the synthesis of maresin conjugate in tissue regeneration 1 (MCTR1), showcasing its role in anti-inflammatory processes and tissue healing.

THERAPEUTIC SIGNIFICANCE:
The exploration of Leukotriene C4 synthase's functions offers a promising avenue for therapeutic intervention. Given its central role in producing compounds with anti-inflammatory and tissue-regenerating effects, targeting this enzyme could yield novel strategies for treating inflammatory diseases and enhancing tissue repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.